"Remission Induction" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Descriptor ID |
D012074
|
MeSH Number(s) |
E02.860
|
Concept/Terms |
Remission Induction- Remission Induction
- Induction, Remission
- Inductions, Remission
- Induction of Remission
- Remission Inductions
|
Below are MeSH descriptors whose meaning is more general than "Remission Induction".
Below are MeSH descriptors whose meaning is more specific than "Remission Induction".
This graph shows the total number of publications written about "Remission Induction" by people in this website by year, and whether "Remission Induction" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 4 | 4 |
1995 | 0 | 17 | 17 |
1996 | 0 | 11 | 11 |
1997 | 0 | 11 | 11 |
1998 | 1 | 8 | 9 |
1999 | 0 | 7 | 7 |
2000 | 0 | 18 | 18 |
2001 | 0 | 8 | 8 |
2002 | 0 | 11 | 11 |
2003 | 0 | 14 | 14 |
2004 | 0 | 15 | 15 |
2005 | 1 | 13 | 14 |
2006 | 0 | 11 | 11 |
2007 | 1 | 16 | 17 |
2008 | 0 | 18 | 18 |
2009 | 0 | 16 | 16 |
2010 | 0 | 12 | 12 |
2011 | 1 | 21 | 22 |
2012 | 1 | 14 | 15 |
2013 | 0 | 15 | 15 |
2014 | 0 | 18 | 18 |
2015 | 0 | 16 | 16 |
2016 | 0 | 15 | 15 |
2017 | 0 | 12 | 12 |
2018 | 1 | 18 | 19 |
2019 | 2 | 17 | 19 |
2020 | 3 | 16 | 19 |
2021 | 0 | 13 | 13 |
2022 | 0 | 8 | 8 |
2023 | 0 | 18 | 18 |
2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Remission Induction" by people in Profiles.
-
Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. J Crohns Colitis. 2024 Feb 26; 18(2):264-274.
-
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts. Leukemia. 2024 02; 38(2):389-392.
-
Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2024 Jan; 65(1):69-77.
-
Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A Prospective Open-label Study. J Crohns Colitis. 2023 Dec 30; 17(12):1897-1909.
-
Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease. Dig Dis Sci. 2024 Feb; 69(2):355-359.
-
Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.
-
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia. 2024 01; 38(1):58-66.
-
A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America. Blood Adv. 2023 09 26; 7(18):5202-5209.
-
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023 11 01; 41(31):4893-4904.
-
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology. 2023 Dec; 165(6):1443-1457.